Ann: PTX-100 Trial Update, page-22

Shellbell, with all due respect, if I had a dollar for every time an MD of a company sat on a discussion panel, and nothing ever came of it, I'd be sipping tropical cocktails in the Bahamas.

Steven's presence on the panel is great but it means nothing more than he happens to work for a company that operates in an exciting and emerging field of biotech. This means nothing materially to PTX holders.

Results do and they take time to surface unfortunately and are usually negative.

It's important fair weight is given to the substantial risks faced by PTX shareholders.